Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro
暂无分享,去创建一个
S. Khoo | D. Back | M. Barry | P. Hoggard | S. Kewn
[1] A. Breckenridge,et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.
[2] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[3] S. Khoo,et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. , 1996, AIDS.
[4] M. Hirsch,et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.
[5] D. Back,et al. Zalcitabine (ddC) Phosphorylation and Drug Interactions , 1995 .
[6] R. Tubiana,et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. , 1995, The Journal of infectious diseases.
[7] A. Cross,et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. , 1995, The Journal of infectious diseases.
[8] D. Back,et al. Drug interactions with zidovudine phosphorylation in vitro. , 1994, Antimicrobial agents and chemotherapy.
[9] D. Back,et al. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. , 1994, British journal of clinical pharmacology.
[10] J. Beijnen,et al. Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.
[11] J. Sommadossi. Nucleoside analogs: similarities and differences. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] B. Gazzard,et al. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients , 1992, Antimicrobial Agents and Chemotherapy.
[13] J. Cameron,et al. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. , 1992, Biochemical pharmacology.
[14] C. H. Chen,et al. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. , 1992, The Journal of biological chemistry.
[15] J. Sommadossi,et al. Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells. , 1991, Molecular pharmacology.
[16] H. Ho,et al. Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. , 1990, Biochemical pharmacology.
[17] F. Harwood,et al. Cytostatic effects of 2',3'-dideoxyribonucleosides on transformed human hemopoietic cell lines. , 1990, Molecular pharmacology.
[18] J. Starrett,et al. 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine. A Highly Potent and Selective Anti-HIV Agent. , 1989 .
[19] H. Ho,et al. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus , 1989, Antimicrobial Agents and Chemotherapy.
[20] M. Hansen,et al. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.
[21] E. De Clercq,et al. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. , 1989, The Journal of biological chemistry.
[22] J. Starrett,et al. 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. , 1989, Journal of medicinal chemistry.
[23] S. Broder,et al. Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders , 1988, Journal of clinical pharmacology.
[24] E. De Clercq,et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro , 1987, Antimicrobial Agents and Chemotherapy.
[25] E. De Clercq,et al. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. , 1987, Molecular pharmacology.
[26] J. Longstreth,et al. Ribavirin disposition in high‐risk patients for acquired immunodeficiency syndrome , 1987, Clinical pharmacology and therapeutics.
[27] R. Schooley,et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication , 1987, Science.
[28] J. Sommadossi,et al. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro , 1987, Antimicrobial Agents and Chemotherapy.
[29] J Desmyter,et al. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. , 1987, Biochemical and biophysical research communications.
[30] S. Broder,et al. Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. , 1986, Biochemical pharmacology.
[31] G. Aronoff,et al. Fluoxetine kinetics and protein binding in normal and impaired renal function , 1984, Clinical pharmacology and therapeutics.
[32] S. Eksborg,et al. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. , 1979, Journal of chromatography.
[33] C. Heusghem,et al. Pharmacokinetic Studies of Co‐Trimoxazole in Man After Single and Repeated Doses , 1974, Journal of clinical pharmacology.
[34] S. Steinberg,et al. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.
[35] S. Broder,et al. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. , 1987, Biochemical pharmacology.